Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of methyl aminolevulinate (Metvix) photodynamic therapy in high-risk patients with superficial basal cell carcinoma
2004-003015-23Phase 3Active
- Sponsor
- Galderma
- Start
- Dec 2005
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of methyl aminolevulinate in basal cell carcinoma (BCC), sponsored by Galderma. Primary endpoint: Primary clinical response at 3 months. Started Dec 2005; status: active.
02
Drugs
methyl aminolevulinate
03
Conditions
basal cell carcinoma (BCC)
Beyond the preview
Go deeper on 2004-003015-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-003015-23.